drugset / Trial / NCT02091414
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant. The anticipated time on study treatment is 24 weeks.
Timeline
- Start
- 2006-08
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mycophenolate Mofetil | Small molecule | 1 g | Oral |
| Background | Cyclosporine | Peptide | 4 mg/kg | — |
| Background | Cyclosporine | Peptide | 6 mg/kg | — |
Indications
No indication recorded.